Stock analysts at StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) in a note issued to investors on Saturday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Trading Up 0.2 %
Galmed Pharmaceuticals stock opened at $0.30 on Friday. The company has a market capitalization of $1.52 million, a P/E ratio of -0.13 and a beta of 0.69. Galmed Pharmaceuticals has a 1-year low of $0.26 and a 1-year high of $2.87. The firm’s fifty day simple moving average is $0.35 and its 200-day simple moving average is $0.37.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last posted its earnings results on Thursday, May 30th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Featured Articles
- Five stocks we like better than Galmed Pharmaceuticals
- How to Calculate Options Profits
- Top 3 Defense Stocks That Should Be on Your Radar
- What is the Nikkei 225 index?
- Why This Banking Stock Might Be Nearing the Bottom of Its Cycle
- How to Invest in Blue Chip Stocks
- MarketBeat Week in Review – 7/8 – 7/12
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.